Document is current
Any future updates will be listed below
-
Authors
Singh, Rishi P.
Tabano, David
Kuo, Blanche L.
LaPrise, Andrew
Leng, Theodore
Kim, Eunice
Hatfield, Meghan
Garmo, Vincent
-
Funding
Funding for this research was provided by:
Genentech (Study support, medical writing support, Study support, medical writing support, Study support, medical writing support, Study support, medical writing support, Study support, medical writing support, Study support, medical writing support, Study support, medical writing support, Study support, medical writing support)
Research to Prevent Blindness
National Institutes of Health (P30-EY026877)
- License Information
-
More Information
Article History
Received: 29 May 2024
Accepted: 2 December 2024
First Online: 30 December 2024
Declarations
:
: No human participants were included in this study. This study adheres to the Declaration of Helsinki. The study was reviewed by WCG Institutional Review Board (IRB) (Puyallup, WA) and was considered exempt from ethical approval due to using anonymized, de-identified data. Furthermore, WCG IRB waived the need for patient consent as Veran Health certified the study was conducted on anonymized, deidentified data for research purposes.
: Not applicable.
: AL and MH: Employee salary; stock or stock options – Verana Health. BLK: No conflicts of interest. DT, EK, and VG: Employee salary; Stock – Genentech, Inc. RPS: Personal fees – Genentech/Roche, Alcon, Novartis/Gyroscope, Apellis, Zeiss, Bausch + Lomb, Regeneron Pharmaceuticals, Inc. TL: Grants/Contracts – Astellas; Consulting fees – Alcon, Aptitude Medical, Astellas, Boehringer Ingelheim, Iridex, Nanoscope, Regeneron, Roche/Genentech, Verana Health, Virtual Field.
